SCN9A and erythromelalgia: This makes pharmacological inhibition of NaV1.7 an exciting therapeutic strategy for the treatment of a wide range of pain types, including inherited erythromelalgia and paroxysmal extreme pain disorder, two conditions whose pathophysiology arises from NaV1.7 gain-of-function mutations.